Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | aurora kinase A | Starlite/ChEMBL | References |
Homo sapiens | aurora kinase B | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | aurora kinase B | 303 aa | 299 aa | 22.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | nitric oxide synthase, putative | 0.1504 | 1 | 1 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0746 | 0.4316 | 0.4316 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.1504 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0575 | 0.3033 | 0.3033 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0575 | 0.3033 | 0.3033 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.1504 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0575 | 0.3033 | 0.5 |
Mycobacterium tuberculosis | Possible oxygenase | 0.0171 | 0 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0746 | 0.4316 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1504 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.1504 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1504 | 1 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0575 | 0.3033 | 0.3033 |
Mycobacterium tuberculosis | Possible electron transfer protein FdxB | 0.0171 | 0 | 0.5 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0575 | 0.3033 | 0.3033 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1504 | 1 | 1 |
Leishmania major | cytochrome P450 reductase, putative | 0.1333 | 0.8717 | 0.8717 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.1504 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.1333 | 0.8717 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0929 | 0.5684 | 1 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0575 | 0.3033 | 0.3033 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0746 | 0.4316 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.1504 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.1504 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0929 | 0.5684 | 0.5684 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.1504 | 1 | 1 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0575 | 0.3033 | 0.3033 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0929 | 0.5684 | 0.5684 |
Brugia malayi | flavodoxin family protein | 0.0575 | 0.3033 | 0.3033 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0575 | 0.3033 | 0.5 |
Onchocerca volvulus | 0.0171 | 0 | 0.5 | |
Entamoeba histolytica | type A flavoprotein, putative | 0.0575 | 0.3033 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.1504 | 1 | 1 |
Echinococcus granulosus | methionine synthase reductase | 0.0929 | 0.5684 | 0.5684 |
Treponema pallidum | flavodoxin | 0.0575 | 0.3033 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.1504 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0929 | 0.5684 | 0.5684 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.1504 | 1 | 1 |
Echinococcus multilocularis | methionine synthase reductase | 0.0929 | 0.5684 | 0.5684 |
Plasmodium falciparum | NADPH--cytochrome P450 reductase, putative | 0.0575 | 0.3033 | 0.3033 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.1504 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.1333 | 0.8717 | 0.8159 |
Loa Loa (eye worm) | hypothetical protein | 0.1504 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.1504 | 1 | 1 |
Plasmodium falciparum | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0575 | 0.3033 | 0.3033 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0171 | 0 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1333 | 0.8717 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.1333 | 0.8717 | 0.8717 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0575 | 0.3033 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0758 | 0.4402 | 0.4402 |
Mycobacterium tuberculosis | Probable monooxygenase | 0.0171 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.1504 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.1504 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0575 | 0.3033 | 0.5 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0575 | 0.3033 | 0.3033 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1504 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.1504 | 1 | 1 |
Mycobacterium tuberculosis | Hypothetical oxidoreductase | 0.0171 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.1504 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 2857 nM | Antiproliferative activity against human A549 cells after 6 to 7 days by celltiter-glo luminescence assay in absence of 70% human serum albumin | ChEMBL. | 20420387 |
IC50 (binding) | = 22 nM | Inhibition of human Aurora B by rapid dilution method | ChEMBL. | 20420387 |
IC50 (binding) | = 2445 nM | Inhibition of human Aurora A | ChEMBL. | 20420387 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 20420387 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.